Edgar Simard Joins BranchLab Scientific Advisory Board

Epidemiology and real-world evidence leader joins interdisciplinary board advancing the scientific foundation of AI for healthcare commercialization.

BOULDER, Colo., Nov. 10, 2026 /PRNewswire/ -- BranchLab today announced that Edgar Simard, PhD, MPH, has joined its Scientific Advisory Board. He brings more than 25 years of experience in epidemiology and real-world evidence to BranchLab as it applies AI to improve commercial decision-making and connect people to relevant therapies and resources.

Simard is Executive Director and Head of Global Epidemiology & RWD Strategy at Revolution Medicines and serves on the BranchLab board in a personal capacity. Throughout his career, he has built and led epidemiology and real-world evidence functions at organizations including Verily, Medtronic, GSK, and Aetion, with earlier research roles at the National Cancer Institute, CDC, American Cancer Society, and Emory University. His work connects scientific evidence with commercial strategy to better understand patient populations, treatment patterns, and unmet need across the product lifecycle.

"Commercial decisions in healthcare increasingly rely on complex data and AI, but they rarely face the same evidentiary standards we expect in clinical research and epidemiology. I'm interested in helping close that gap in a fit-for-purpose way: Making sure the populations these models describe are well defined and the methods are transparent and rigorous. BranchLab is well positioned to move the industry forward because of its multidisciplinary approach and grounding in scientific best practice, and I look forward to contributing to that work," said Simard.

Simard joins a Scientific Advisory Board built on the belief that no single discipline can address the challenges at the intersection of AI and healthcare commercialization. The board brings complementary perspectives across AI, healthcare, human-AI collaboration, and population science to guide BranchLab's scientific direction, with a core focus on Pathwai™, BranchLab's Semantic Activation Platform.

"Dr. Simard brings a perspective that spans the pharmaceutical lifecycle, from scientific discovery to real-world impact," said Kat Drake, PhD, Vice President of Data Science & AI at BranchLab. "He understands how real-world data can create robust scientific evidence and inform meaningful decisions within healthcare organizations. That experience adds valuable context to the development of Pathwai and how we help healthcare organizations understand patient populations and make better commercial decisions."

Simard has published more than 50 peer-reviewed papers spanning cancer epidemiology, population health, and global disease burden, with his research cited more than 60,000 times. His work has included leadership on the Global Burden of Disease studies and the Annual Report to the Nation on the Status of Cancer. He holds a PhD in Epidemiology from Rutgers University and an MPH in Epidemiology from Emory University.

More information about the BranchLab Scientific Advisory Board and its members is available at branchlab.com/scientific-advisory-board.

ABOUT BRANCHLAB
BranchLab is transforming healthcare commercialization with Pathwai™, the industry's first Semantic Activation Platform. Its AI-native technology helps leading healthcare organizations and their agencies connect patients, providers, and caregivers to life-improving therapies and resources. Built for the evolving privacy landscape, BranchLab improves commercialization performance without relying on individual-level health information. By modernizing the industry's technical infrastructure, BranchLab helps organizations operate more efficiently and responsibly, while enabling a healthier system for everyone.

To learn more, visit www.branchlab.com.

Media Contact
[email protected]

SOURCE BranchLab Inc